Tango Therapeutics, Inc.

Historical 13F Holders

Symbol
TNGX
CUSIP
87583X109
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 87583X109 since 12/18/2024, largest first.

Filer % of Class Filed
BCTG Holdings, LLC 13D/A
10.0% 1/2/2025
Event 12/30/2024
Farallon Partners L L C/CA 13G/A
10.0% 2/6/2026
Event 12/31/2025
Farallon Capital Management, L.L.C. 13G/A
9.8% 8/14/2026
Event 6/30/2026
RTW Investments, LP 13G
9.3% 5/15/2026
Event 3/31/2026
Farallon Capital Partners, L.P. 13G/A
7.8% 5/11/2026
Event 3/31/2026
TCG Crossover GP II, LLC 13G/A
7.0% 8/14/2026
Event 6/30/2026
FMR LLC 13G
6.9% 5/6/2026
Event 3/31/2026
BlackRock, Inc. 13G 6.3% 1/21/2026
Event 12/31/2025
Goldman Sachs Group Inc 13G
6.0% 8/14/2026
Event 6/30/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (7)
Third Rock Ventures IV, L.P. 13D/A
4.7% 2/10/2026
Event 2/6/2026
Invus Global Management, LLC 13G/A
4.0% 5/4/2026
Event 3/31/2026
Adage Capital Management, L.P. 13G/A
3.4% 8/12/2026
Event 6/30/2026
Woodline Partners LP 13G/A 2.5% 8/14/2026
Event 6/30/2026
EcoR1 Capital, LLC 13G/A
0% 2/17/2026
Event 12/31/2025
Nextech Crossover I GP S.a r.l. 13G/A
0% 8/14/2026
Event 6/30/2026
Vanguard Group Inc 13G/A 0% 3/27/2026
Event 3/13/2026

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 9 1.19 M $29.8 M
2026 Q2 260 218 M $6.73 B
2026 Q1 201 180 M $3.78 B
2025 Q4 177 173 M $1.53 B
2025 Q3 148 140 M $1.18 B
2025 Q2 121 127 M $653 M
2025 Q1 125 107 M $147 M
2024 Q4 141 106 M $329 M
2024 Q3 125 102 M $782 M
2024 Q2 126 98.9 M $849 M
2024 Q1 134 98.9 M $785 M
2023 Q4 127 94.3 M $934 M
2023 Q3 101 88.8 M $1.00 B
2023 Q2 90 68.3 M $227 M
2023 Q1 95 69.9 M $276 M
2022 Q4 85 69.6 M $505 M
2022 Q3 90 68.2 M $247 M
2022 Q2 78 70.5 M $319 M
2022 Q1 73 69.7 M $528 M
2021 Q4 60 67.9 M $742 M
2021 Q3 47 65.5 M $845 M